Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Court Finds Data Manipulation, but Not False Advertising: Diovan Case
A former employee of Novartis Pharma tampered with data involving the company’s major hypertension drug Diovan (valsartan), but the publication of scientific papers based on the manipulated data does not constitute false or misleading advertising banned under the law, according…
To read the full story
Related Article
- Japan Top Court Rejects Prosecutors’ Appeal in Diovan Case; Novartis Not Guilty
June 30, 2021
- High Court Upholds Not-Guilty Ruling for Novartis, Ex-Employee in Diovan Case
November 20, 2018
- Tokyo Prosecutors File Appeal in Diovan Case
March 30, 2017
- Novartis Vows Continued Reforms despite Not-Guilty Diovan Ruling
March 17, 2017
- Recovering Trust in Clinical Research Is Urgent Task: Shiozaki
March 17, 2017
- Novartis, Ex-Employee Found Not Guilty in Diovan Case
March 16, 2017
- Diovan Data Manipulation Case Closed, Ruling Due Out in March
December 16, 2016
- Prosecutors Seek 2.5 Years in Jail for Ex-Novartis Employee: Diovan Case
November 28, 2016
- Ex-Novartis Employee Pleads Not Guilty over Diovan Data Manipulation
December 17, 2015
- Ex-Novartis Employee, Japan Unit Indicted over Diovan Data Manipulation
July 1, 2014
- Ex-Novartis Employee Suspected of Manipulating the Number of Events in Sub-Analysis
June 13, 2014
BUSINESS
- Leqembi FY2025 Global Sales Reach 88 Billion Yen: Eisai
May 1, 2026
- Rohto Files CMV Corneal Endotheliitis Drug in Japan
May 1, 2026
- Mochida Files in Japan for PAH Drug Tyvaso DPI
May 1, 2026
- Tanabe Clinches EU Approval for Parkinson’s Drug Onerji
May 1, 2026
- 3D “Deeply Disappointed” by Toho Plan to Seek Defense Trigger Approval
May 1, 2026
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…